CAR-T cells: the long and winding road to solid tumors

被引：329

作者：

D'Aloia, Maria Michela ^{[1
]}

Zizzari, Ilaria Grazia ^{[2
]}

Sacchetti, Benedetto ^{[3
]}

Pierelli, Luca ^{[2
]}

Alimandi, Maurizio ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy

[2] Sapienza Univ Rome, Dept Expt Med, Rome, Italy

[3] Univ Roma Tre, Dept Sci, Rome, Italy

来源：

CELL DEATH & DISEASE | 2018年 / 9卷

关键词：

CHIMERIC ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY THERAPY; I CLINICAL-TRIAL; SLEEPING-BEAUTY; INFILTRATING LYMPHOCYTES; ANTITUMOR-ACTIVITY; IMPROVED SURVIVAL; ADOPTIVE TRANSFER; OXIDATIVE STRESS; EFFECTOR-CELLS;

D O I：

10.1038/s41419-018-0278-6

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surrounding the neoplastic foci. The intricate net of cross-interactions occurring between tumor components, stromal and immune cells leads to an ineffective anergic status favoring the evasion from the host's defenses. Our goal is hereby to trace the road imposed by solid tumors to CAR-T cells, highlighting pitfalls and strategies to be developed and refined to possibly overcome these hurdles.

引用

页数：12

共 108 条

[1] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[2] TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β [J].

Arumugam, Vidhyalakshmi ;

Bluemn, Theresa ;

Wesley, Erin ;

Schmidt, Amanda M. ;

Kambayashi, Taku ;

Malarkannan, Subramaniam ;

Riese, Matthew J. .

JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 98 (05) :703-712

[3]

Badhiwala J, 2013, EXPERT REV NEUROTHER, V13, P405, DOI [10.1586/ern.13.23, 10.1586/ERN.13.23]

[4] Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer [J].

Bakema, Jantine E. ;

van Egmond, Marjolein .

FC RECEPTORS, 2014, 382 :373-392

[5] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].

Beatty, Gregory L. ;

Haas, Andrew R. ;

Maus, Marcela V. ;

Torigian, Drew A. ;

Soulen, Michael C. ;

Plesa, Gabriela ;

Chew, Anne ;

Zhao, Yangbing ;

Levine, Bruce L. ;

Albelda, Steven M. ;

Kalos, Michael ;

June, Carl H. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120

[6] Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Treves, Avraham J. ;

Zippel, Dov ;

Itzhaki, Orit ;

Hershkovitz, Liat ;

Levy, Daphna ;

Kubi, Adva ;

Hovav, Einat ;

Chermoshniuk, Natalia ;

Shalmon, Bruria ;

Hardan, Izhar ;

Catane, Raphael ;

Markel, Gal ;

Apter, Sara ;

Ben-Nun, Alon ;

Kuchuk, Iryna ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2010, 16 (09) :2646-2655

[7] Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Treves, Avraham J. ;

Zippel, Dov ;

Itzhaki, Orit ;

Schallmach, Ester ;

Kubi, Adva ;

Shalmon, Bruria ;

Hardan, Izhar ;

Catane, Raphael ;

Segal, Eran ;

Markel, Gal ;

Apter, Sara ;

Ben Nun, Alon ;

Kuchuk, Iryna ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (04) :415-423

[8] Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity [J].

Bollard, CM ;

Rössig, C ;

Calonge, MJ ;

Huls, MH ;

Wagner, HJ ;

Massague, J ;

Brenner, MK ;

Heslop, HE ;

Rooney, CM .

BLOOD, 2002, 99 (09) :3179-3187

[9] Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer [J].

Bracci, L. ;

Schiavoni, G. ;

Sistigu, A. ;

Belardelli, F. .

CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :15-25

[10] Myeloid cells as effector cells for monoclonal antibody therapy of cancer [J].

Braster, Rens ;

O'Toole, Tom ;

van Egmond, Marjolein .

METHODS, 2014, 65 (01) :28-37

← 1 2 3 4 5 6 7 8 9 10 →